康众医疗公告，预计2025年年度实现归属于母公司所有者的净利润与上年同期相比，将减少2265.27万 元到2665.27万元，同比减少128.32%到150.98%，实现归属于母公司所有者的净利润为负，预计在-900 万元到-500万元之间。 ...

*ST波导公告，预计2025年年度实现归属于母公司所有者的净利润为600万元到800万元。公司预计2025 年年度实现营业收入为4.5亿元到4.9亿元，扣除与主营业务无关的业务收入和不具备商业实质的收入后 的营业收入为4.2亿元到4.6亿元。 ...

万达电影公告，预计2025年度净利润为4.8亿元～5.5亿元，上年同期为-9.4亿元。2025年，公司依托超 过700家直营影院体系和8000万线上会员优势，凭借高效的经营管理能力与"五星级影城"服务品质，进 一步夯实行业领先地位。报告期内，公司实现票房76.78亿元(含服务费)，同比增长18.53%，观影人次 1.63亿，同比增长14.76%，市场份额连续17年稳居行业首位。 ...

Core Insights - The National Press and Publication Administration announced the approval of 182 game licenses in January 2026, including 177 domestic and 5 imported games, maintaining a relatively high issuance level [1] - In 2025, a total of 1,771 game licenses were issued, significantly surpassing the 1,416 licenses in 2024, marking the highest issuance since 2019 [1] - Major companies such as Tencent, NetEase, and others received approvals for key products, including Tencent's "Rainbow Six: Siege" and NetEase's "Yao Yao Chess" [1] Group 1 - The January 2026 approvals included significant titles from major gaming companies, indicating a robust market for both domestic and imported games [1] - Tencent's "Rainbow Six: Siege" is a tactical shooter developed by Ubisoft and is part of Tencent's strategy to enhance its gaming portfolio through partnerships [2][4] - The approval of "Angry Birds: Classic Return" and "Angry Birds: Dream Blast" by Kingsoft's subsidiary marks a strategic partnership aimed at reintroducing the franchise to the Chinese market [4] Group 2 - Tencent's investment of €1.16 billion in Ubisoft's subsidiary Vantage Studios grants it a 26.32% stake, integrating key IPs like "Assassin's Creed" and "Rainbow Six," which helps alleviate Ubisoft's financial pressure [4] - The "Rainbow Six: Siege" team is focused on creating a fair competitive environment and enhancing local services for the Chinese market, indicating a commitment to localization and community engagement [4] - Kingsoft's strategic partnership with Rovio aims to facilitate the exclusive distribution and operation of the "Angry Birds" series in China, highlighting the importance of collaboration in the gaming industry [4]

天威视讯公告，公司与深圳市幸福健康产业(集团)有限公司于2026年1月27日签署了《战略合作框架协 议》。根据协议，双方将在智慧康养服务领域开展合作，公司为幸福健康集团提供全场景智慧网络融合 解决方案及家庭用户服务能力，幸福健康集团为公司提供线下服务场景及行业资源优势。协议有效期为 3年，到期后可自动延续。 ...

同济科技公告，2025年10月至12月，公司新签施工合同额约人民币11.48亿元，较上年同期增长 85.46%；其中超过1000万元以上的施工合同11个，合同金额累计11.1亿元。2025年1-12月，公司新签施 工合同额合计人民币39.78亿元，较上年同期减少2.00%。 ...

Core Viewpoint - The announcement indicates that the drug candidate BPI-572270, developed by the company's wholly-owned subsidiary Jingyao Biotech, has received approval from the National Medical Products Administration for clinical trials in patients with advanced malignant solid tumors [1] Group 1: Drug Development - BPI-572270 is a new molecular entity that the company has independently developed and holds complete intellectual property rights [1] - It is characterized as a novel and potent pan-RAS non-degradable molecular glue inhibitor [1] Group 2: Mechanism of Action - The mechanism of action involves inducing the chaperone protein Cyclophilin A (CYPA) to bind to activated mutant RAS proteins, leading to conformational changes in RAS proteins [1] - This process prevents RAS proteins from binding to downstream signaling proteins, such as cRAF, thereby blocking the MAPK signaling pathways responsible for tumor growth [1]

*ST金比公告，预计2025年度净利润为负值。预计利润总额为-2亿元至-1.4亿元，同比下降297.83%至 382.61%；归属于上市公司股东的净利润为-1.9亿元至-1.3亿元，同比下降349.28%至464.33%；扣除非经 常性损益后的净利润为-1.2亿元至-8000万元，同比下降76.53%至164.80%；基本每股收益为-0.54元 至-0.37元；营业收入为3.5亿元至3.8亿元，上年同期为2.25亿元。 ...

当地时间1月26日，美国稀土公司（USA Rare Earth）宣布获得美国政府约16亿美元的战略投资，这笔 美国政府在该领域最大规模的投资，立即引爆资本市场，该公司股价开盘大幅飙升28%，截至收盘涨 7.8%，报26.72美元。 这已是特朗普政府去年以来至少第六次入股矿业公司，一系列动作表明，美国正通过国家资本直接介入 关键矿产供应链，加速构建本土稀土产能，以减少对海外资源的依赖。 战略注资 美国政府对稀土领域的投资正在形成明确模式：以国家安全为名，通过直接持股方式深度介入私营企 业。 美国政府此次对美国稀土公司的投资组合分为两大核心部分：一是美国政府以每股17.17美元的价格， 出资2.77亿美元收购美国稀土公司1610万股普通股及1760万股认股权证，交易完成后将持有该公司10% 股权；二是美国稀土公司将获得13亿美元的高级有担保债务融资，利率按市场水平执行。 这些资金均来源于2022年《芯片与科学法案》为美国商务部设立的专项融资机制。 总部位于俄克拉荷马州的美国稀土公司是美国稀土产业链垂直一体化布局的核心企业。公司目前正推进 两大关键项目：一是在得克萨斯州锡耶拉布兰卡开发大型稀土矿山，该矿山蕴含17种 ...

Group 1 - The 19th Asian Financial Forum, co-hosted by the Hong Kong SAR government and the Hong Kong Trade Development Council, introduced the "Global Industry Summit" focusing on high-growth and high-value sectors such as biomedicine and healthcare [1] - Junshi Biosciences, a key exhibitor in the biomedicine sector, showcased its technological breakthroughs, product pipeline, and commercialization prospects in the TIL (tumor-infiltrating lymphocyte) therapy field [1] - The company submitted its listing application to the Hong Kong Stock Exchange in December last year and has completed multiple financing rounds totaling nearly 800 million RMB, with a recent C round completed in November 2025, achieving a valuation of 2.137 billion RMB [1] Group 2 - Junshi Biosciences' core product, GC101, is the world's first natural TIL cell new drug that does not require high-intensity lymphodepletion chemotherapy or IL-2 administration, providing long-term benefits to patients with advanced metastatic solid tumors [2] - The product has shown complete tumor clearance in multiple patients, with the longest progression-free survival exceeding 4 years [2] - The company is also actively developing the world's first in-vivo TIL therapy, aiming to shift TIL therapy from a "highly personalized" to a "quasi-off-the-shelf" model, significantly reducing production costs and patient wait times, thereby enhancing accessibility [2]